8 Sources of evidence considered by the Committee

A. The Evidence Review Group (ERG) report for this appraisal was prepared by Aberdeen HTA:

  • Fielding S, Cummins E, Cruickshank M et al. Aflibercept for the treatment of diabetic macular oedema: a single technology appraisal. Aberdeen HTA Group, 2014

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document. Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to make written submissions. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I. Company:

  • Bayer Pharma

II. Professional/expert and patient/carer groups:

  • Diabetes UK

  • Fight for Sight

  • Royal National Institute of Blind People (RNIB)

  • Royal College of Ophthalmologists

  • Royal College of Physicians

III. Other consultees:

  • Department of Health

  • NHS England

  • NHS Stafford & Surrounds Clinical Commissioning Group

  • Welsh Government

IV. Commentator organisations (did not provide written evidence and without the right of appeal):

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Healthcare Improvement Scotland

  • Alimera Sciences

  • Novartis Pharmaceuticals

  • Roche Products

C. The following individuals were selected from clinical expert and patient expert nominations from the consultees and commentators. They gave their expert personal view on aflibercept for treating diabetic macular oedema by attending the initial Committee discussion and providing a written statement to the Committee. They were also invited to comment on the ACD.

  • Ian Pearce, Consultant Ophthalmologist, nominated by Bayer Pharma – clinical expert

  • Sobha Sivaprasad, Consultant Ophthalmologist, nominated by Royal College of Ophthalmologists, endorsed by RNIB, Macular Society and Diabetes UK – clinical expert

  • Clara Eaglen, Policy and Campaigns Manager, nominated by RNIB – patient expert

  • Clive Worrall, nominated by RNIB – patient expert

D. Representatives from the following company attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Bayer Pharma

  • National Institute for Health and Care Excellence (NICE)